{
  "id": 17803244,
  "title": "Granules India Q2 FY27 slides: record revenue amid margin pressure",
  "url": "https://urgent.news/2026/11/02/granules-india-q2-fy27-slides-record-revenue-amid-margin-pressure",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-02T13:52:43.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/granules-india-q2-fy27-slides-record-revenue-amid-margin-pressure-93CH-4991795"
  },
  "original_language": "en",
  "account": "Granules India Limited reported Q2 FY27 earnings on November 2, 2026, achieving record revenue of ₹15,600 million, marking a 20% year-over-year increase. Despite this strong top-line growth, the pharmaceutical manufacturer's stock declined 2.27% to $820.7 after investors considered margin compression due to elevated freight costs and new FDA observations at the Gagillapur facility. Gross margins contracted 134 basis points year-over-year to 64.4%, driven by geopolitical tensions in West Asia that inflated input and logistics expenses. Chairman and Managing Director Dr. Krishna Prasad Chigurupati acknowledged the challenges, noting revenue surpassing ₹1,500 crore and EBITDA of ₹338 crore, despite operational pressures. The company successfully concluded a US FDA audit at Gagillapur with 11 addressable observations, none concerning data integrity or cross-contamination. Granules' growth drivers include robust North American sales (72% of total sales) and a diverse product portfolio, with complex generics accounting for 49% of Finished Dosages revenue. The company's capital structure shows significant improvements, including a net cash position of ₹8,280 million in Q2 FY27 versus net debt of ₹1,012 million in Q1 FY27, and a ROCE that increased by 138 basis points year-over-year to 17.6%.",
  "summary": null,
  "key_points": [
    "Granules India reported ₹15,600 million revenue in Q2 FY27, a 20% YoY increase.",
    "Margin compression led to stock decline 2.27% to $820.7 after freight cost hikes.",
    "Chairman acknowledged challenges despite revenue surpassing ₹1,500 crore and EBITDA of ₹338 crore."
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Hindu BusinessLine",
        "title": "India’s sugar production up at a record high of 8.5 lakh tonnes in October",
        "url": "https://urgent.news/2026/11/02/indias-sugar-production-up-at-a-record-high-of-8-5-lakh-tonnes-in",
        "published": "2026-11-02T15:22:09.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}